Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + chidamide + rituximab as first-line therapy in elderly patients with double-expressor DLBCL
ChiCTR2500098804Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib, tucidinostat and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Fujian Medical University Union Hospital. Primary endpoint: 2-year progression-free survival. Started Mar 2025; status: recruiting.
02
Drugs
zanubrutinibtucidinostatrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2500098804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098804.